Jan 18 (Reuters) - PCI BIOTECH HOLDING ASA:
* EXTENDING PRECLINICAL RESEARCH COLLABORATION WITH UNDISCLOSED TOP-10 PHARMA COMPANY, INITIATED IN SEPTEMBER 2015â€‹
* WILL EVALUATE DATA GENERATED AND EXPLORE POTENTIAL FOR FURTHER PARTNERSHIP BASED ON OUTCOME
* - EXTENDED EVALUATION PERIOD SPANS OVER 6 MONTHS, UNTIL THE END OF JUNE 2018, AND MAY BE FURTHER EXTENDED Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 